168 related articles for article (PubMed ID: 37037790)
1. ROCK inhibitors in ophthalmology: A critical review of the existing clinical evidence.
Karri R; Chong EW
Clin Exp Ophthalmol; 2023 Jul; 51(5):472-483. PubMed ID: 37037790
[TBL] [Abstract][Full Text] [Related]
2. Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology.
Moura-Coelho N; Tavares Ferreira J; Bruxelas CP; Dutra-Medeiros M; Cunha JP; Pinto Proença R
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1101-1117. PubMed ID: 30843105
[TBL] [Abstract][Full Text] [Related]
3. ROCK Inhibitors as an Alternative Therapy for Corneal Grafting: A Systematic Review.
Polopalli S; Saha A; Niri P; Kumar M; Das P; Kamboj DV; Chattopadhyay P
J Ocul Pharmacol Ther; 2023 Nov; 39(9):585-599. PubMed ID: 37738326
[TBL] [Abstract][Full Text] [Related]
4. ROCK Inhibitors in Corneal Diseases and Glaucoma-A Comprehensive Review of These Emerging Drugs.
Pagano L; Lee JW; Posarelli M; Giannaccare G; Kaye S; Borgia A
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959203
[TBL] [Abstract][Full Text] [Related]
5. The Role of Rho Kinase Inhibitors in Corneal Diseases.
Futterknecht S; Chatzimichail E; Gugleta K; Panos GD; Gatzioufas Z
Drug Des Devel Ther; 2024; 18():97-108. PubMed ID: 38264539
[TBL] [Abstract][Full Text] [Related]
6. The Role of Rho Kinase Inhibitors in Corneal Endothelial Dysfunction.
Okumura N; Kinoshita S; Koizumi N
Curr Pharm Des; 2017; 23(4):660-666. PubMed ID: 27917718
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Rho-associated protein kinase activity enhances oxidative phosphorylation to support corneal endothelial cell migration.
Ho WT; Chang JS; Chen TC; Wang JK; Chang SW; Yang MH; Jou TS; Wang IJ
FASEB J; 2022 Jul; 36(7):e22397. PubMed ID: 35661268
[TBL] [Abstract][Full Text] [Related]
8. Corneal Endothelial Cell Migration and Proliferation Enhanced by Rho Kinase (ROCK) Inhibitors in In Vitro and In Vivo Models.
Meekins LC; Rosado-Adames N; Maddala R; Zhao JJ; Rao PV; Afshari NA
Invest Ophthalmol Vis Sci; 2016 Dec; 57(15):6731-6738. PubMed ID: 27951595
[TBL] [Abstract][Full Text] [Related]
9. An update on ripasudil for the treatment of glaucoma and ocular hypertension.
Testa V; Ferro Desideri L; Della Giustina P; Traverso CE; Iester M
Drugs Today (Barc); 2020 Sep; 56(9):599-608. PubMed ID: 33025953
[TBL] [Abstract][Full Text] [Related]
10. Rho kinase (ROCK) inhibitors in the management of corneal endothelial disease.
Syed ZA; Rapuano CJ
Curr Opin Ophthalmol; 2021 May; 32(3):268-274. PubMed ID: 33606407
[TBL] [Abstract][Full Text] [Related]
11. Effects of Rho-Associated Kinase (Rock) Inhibitors (Alternative to Y-27632) on Primary Human Corneal Endothelial Cells.
Peh GSL; Bandeira F; Neo D; Adnan K; Hartono Y; Ong HS; Naso S; Venkatraman A; Gomes JAP; Kocaba V; Mehta JS
Cells; 2023 May; 12(9):. PubMed ID: 37174707
[TBL] [Abstract][Full Text] [Related]
12. Effect of the Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) on Corneal Endothelial Wound Healing.
Okumura N; Okazaki Y; Inoue R; Kakutani K; Nakano S; Kinoshita S; Koizumi N
Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):1284-92. PubMed ID: 26998714
[TBL] [Abstract][Full Text] [Related]
13. Rho-kinase inhibitors in the management of glaucoma.
Berrino E; Supuran CT
Expert Opin Ther Pat; 2019 Oct; 29(10):817-827. PubMed ID: 31573364
[No Abstract] [Full Text] [Related]
14. Potential Functional Restoration of Corneal Endothelial Cells in Fuchs Endothelial Corneal Dystrophy by ROCK Inhibitor (Ripasudil).
Schlötzer-Schrehardt U; Zenkel M; Strunz M; Gießl A; Schondorf H; da Silva H; Schmidt GA; Greiner MA; Okumura N; Koizumi N; Kinoshita S; Tourtas T; Kruse FE
Am J Ophthalmol; 2021 Apr; 224():185-199. PubMed ID: 33316261
[TBL] [Abstract][Full Text] [Related]
15. Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature.
Moshirfar M; Parker L; Birdsong OC; Ronquillo YC; Hofstedt D; Shah TJ; Gomez AT; Hoopes PCS
Med Hypothesis Discov Innov Ophthalmol; 2018; 7(3):101-111. PubMed ID: 30386798
[TBL] [Abstract][Full Text] [Related]
16. Evolving indications for Descemet's stripping automated endothelial keratoplasty.
Veldman PB; Terry MA; Straiko MD
Curr Opin Ophthalmol; 2014 Jul; 25(4):306-11. PubMed ID: 24871355
[TBL] [Abstract][Full Text] [Related]
17. Reticular epithelial corneal edema as a novel side-effect of Rho Kinase Inhibitors: An Indian scenario.
Bhargava M; Sen S; Bhambhani V; Paul RS; Dutta C
Indian J Ophthalmol; 2022 Apr; 70(4):1163-1170. PubMed ID: 35326007
[TBL] [Abstract][Full Text] [Related]
18. Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Transiently Alters the Morphology of Corneal Endothelial Cells.
Okumura N; Okazaki Y; Inoue R; Nakano S; Fullwood NJ; Kinoshita S; Koizumi N
Invest Ophthalmol Vis Sci; 2015 Nov; 56(12):7560-7. PubMed ID: 26618648
[TBL] [Abstract][Full Text] [Related]
19. Descemet's membrane in the iridocorneal-endothelial syndrome: morphology and composition.
Levy SG; McCartney AC; Sawada H; Dopping-Hepenstal PJ; Alexander RA; Moss J
Exp Eye Res; 1995 Sep; 61(3):323-33. PubMed ID: 7556496
[TBL] [Abstract][Full Text] [Related]
20. The ROCK Inhibitor Ripasudil Shows an Endothelial Protective Effect in Patients With Low Corneal Endothelial Cell Density After Cataract Surgery.
Fujimoto H; Setoguchi Y; Kiryu J
Transl Vis Sci Technol; 2021 Apr; 10(4):18. PubMed ID: 34003995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
